TNFRSF17 and myasthenia gravis: B-cell maturation antigen (BCMA), primarily expressed in plasmablasts and plasma cells (PB/PCs) at high levels (Mikkilineni and Kochenderfer, 2021), represents a promising target antigen for novel therapies in autoantibody seropositive MG.